Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

Treatment of chronic hepatitis B (CHB) typically requires life-long administration of drugs. Cohort and pre-clinical studies have established the link between a functional T-cell-mounted immunity and resolution of infection. TG1050 is an adenovirus 5-based vaccine that expresses HBV polymerase and d...

Descripción completa

Detalles Bibliográficos
Autores principales: Zoulim, Fabien, Fournier, Claire, Habersetzer, François, Sprinzl, Martin, Pol, Stanislas, Coffin, Carla S, Leroy, Vincent, Ma, Mang, Wedemeyer, Heiner, Lohse, Ansgar W, Thimme, Robert, Lugardon, Karine, Martin, Perrine, Bastien, Bérangère, Sansas, Benoit, Adda, Nathalie, Halluard, Celine, Bendjama, Kaïdre, Brandely, Maud, Inchauspé, Geneviève
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158919/
https://www.ncbi.nlm.nih.gov/pubmed/31373537
http://dx.doi.org/10.1080/21645515.2019.1651141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158919/
https://www.ncbi.nlm.nih.gov/pubmed/31373537
http://dx.doi.org/10.1080/21645515.2019.1651141

Ejemplares similares